SBIR Phase II: Multi-Marker Prognostic Test for Breast Cancer Outcome

SBIR II 期：乳腺癌结果的多标志物预后测试

• 批准号: 0750452
• 负责人: Albert Man
• 金额: $ 49.97万
• 依托单位: PREDICTION SCIENCES, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2012-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0750452&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Multi; Marker

This Small Bbusiness Innovation Research (SBIR) Phase II project aims to continue the validation of a set of markers for predicting recurrence and guiding the selection of treatment in stage I-III breast cancer patients. Upon removal of their primary stage I-III operable tumors, breast cancer patients must decide whether or not to receive adjuvant therapy such as chemotherapy, or hormone therapy. Currently, the physician and patient can arrive at the decision by relying on several published guidelines whose accuracy is limited by the fact that they are based on general clinicopathologic data such as tumor size and grade. Thus the majority of patients are recommended to receive adjuvant therapy, although only a small fraction of them benefit from it. Availability of a set of reliable markers that can predict recurrence of tumors would allow tailoring of adjuvant therapy for each patient and is thus likely to reduce the chances of under-treatment and over-treatment. As such, it would be of great benefit to cancer patients, as well as to oncologists.

这个小企业创新研究（SBIR）二期项目旨在继续验证一组用于预测I-III期乳腺癌患者复发和指导治疗选择的标志物。原发性I-III期可手术肿瘤切除后，乳腺癌患者必须决定是否接受辅助治疗，如化疗或激素治疗。目前，医生和患者可以依靠一些已发表的指南来做出决定，这些指南的准确性受到基于一般临床病理数据（如肿瘤大小和分级）的限制。因此，大多数患者被推荐接受辅助治疗，尽管只有一小部分患者从中受益。一组可靠的标记物的可用性可以预测肿瘤的复发，这将允许为每个患者量身定制辅助治疗，从而可能减少治疗不足和过度治疗的机会。因此，这对癌症患者和肿瘤学家都有很大的好处。